PureCycle Technologies heads into its Q1 2026 earnings today carrying one of the most heavily shorted profiles in the US market — and a recent 40% price rally that has done nothing to shake the bears.
Short interest in PCT is deeply entrenched. Nearly 29% of the free float is sold short, with days to cover running at 17.5 — meaning it would take shorts more than three weeks to unwind at current trading volumes. The ORTEX short score hit 88.6 out of 100 on May 5, a level that places PCT in the very top tier of short conviction across the entire universe, and it has climbed steadily for the past two weeks. Despite the stock adding 41% over the past month to close at $7.62, short sellers have actually added exposure: short shares have risen roughly 8% over the same period. Borrow availability has tightened meaningfully too, with the lending pool nearly fully drawn at 93.7% utilisation. Cost to borrow has roughly doubled over the past month to 13%, reflecting that increasing demand to hold the position.
Options positioning adds to the cautious tone heading into the print. The put/call ratio has moved meaningfully above its recent average, running at 0.54 against a 20-day mean near 0.49. That reading is 2.5 standard deviations above the norm — the highest defensive posture in nearly a year — pointing to elevated demand for downside protection. The combination of extreme short interest, tightening availability, and an elevated put/call ratio describes a market that remains deeply sceptical, even as the stock has bounced hard off its February lows.
The February earnings result frames just how high the bar is. The last print sent PCT down 29% in a single session and 32% over the following five days — a severe reaction that appears to have cemented the bear camp's conviction. The analyst consensus, last updated in early March, shows a mean price target of $11.83 — roughly 55% above current levels — but the direction of travel has been negative. Cantor Fitzgerald maintained its Overweight rating after that print while cutting its target to $14. TD Cowen downgraded to Hold with a $9 target back in late 2024 after previously holding a Buy. The bull case rests on improving gross margins — estimates of 25% for FY26 rising to 30% for FY27 — and sharply higher UPR resin volumes, with FY26 projections at 91 million pounds. Bears counter that scaling the dissolution process reliably and securing consistent feedstock supply remain unproven at commercial volumes, and that unit economics are yet to justify the capital structure.
Abundance Wealth Counselors added 6.7 million shares in Q1 2026, one of the largest disclosed institutional moves in the holder table, suggesting at least one fresh buyer with conviction. Yet the C-suite has been a consistent seller: CEO Dustin Olson sold shares in February and again in March, as did the CFO and Chief Compliance Officer — all at prices well below today's level, and all tied to compensation-related awards, but the direction of insider cash flow has been outward. Today's print is therefore a direct test of whether PCT's operational ramp in early 2026 can begin to close the gap between the bull case on margins and volumes and the bear thesis on execution risk that the short book has been pricing in all year.
See the live data behind this article on ORTEX.
Open PCT on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
